Effects of pretreatment with Yisheng injection on renal warm ischemia/reperfusion injury in mice.
BACKGROUND
Due to the organ supply shortage, the donor pool has been expanded to include non-heart-beating donors, where renal warm ischemia/reperfusion (I/R) injury is inevitable. This study was undertaken to determine whether Yisheng injection (YM) could attenuate renal warm I/R injury in mice.


METHODS
Male C57BL/6 mice were divided into sham, ischemic, and YM-treated groups using 50 minutes of left kidney ischemia. Mice were humanely killed at 4 or 24 hours postreperfusion. We assayed the effects of YM on liver functional injury, neutrophil recruitment, and proinflammatory mediators after renal I/R injury.


RESULTS
Renal I/R produced dramatic injuries in mouse kidneys. Administration of YM reduced liver function (urea nitrogen of untreated vs treated, 4.7 +/- 0.6 vs 26.6 +/- 1.5 mmol/L; P < .01) and histological injury (histological scores of untreated vs treated, 4.12 +/- 0.14 vs 0.98 +/- 0.07; P < .01). YM at doses of 5, 15, or 25 mg/kg reduced the serum levels of tumor necrosis factor-alpha (TNF-alpha) by about 32.9%, 55.1%, and 74.5%, respectively. Moreover, YM also suppressed the increase in messenger RNA (mRNA) and protein expressions of TNF-alpha and intercellular adhesion molecule-1 (ICAM-1), as well as abrogated neutrophil recruitment in a dose-dependent manner.


CONCLUSIONS
YM protects murine kidneys from warm I/R injury, probably via decreasing functional injury, reducing neutrophil infiltration, and suppressing the overexpression of proinflammatory mediators and adhesion molecules.
Feng
L
L
Key Laboratory of Transplant Engineering and Immunology of Health Ministry of China, and Hepato-bilio-pancreatic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan Province, People's Republic of China.
Guo
Y
Y
Cheng
F
F
Li
S
S
Wei
L
L
Long
D
D
Li
Q
Q
Li
Y
Y
D000818:Animals; D001600:Berberine Alkaloids / Q000737:chemistry / Q000627:therapeutic use; D004365:Drugs, Chinese Herbal / Q000737:chemistry / Q000627:therapeutic use*; D007150:Immunohistochemistry; D018799:Intercellular Adhesion Molecule-1 / Q000235:genetics; D007668:Kidney / Q000187:drug effects / Q000473:pathology; D008099:Liver / Q000187:drug effects / Q000473:pathology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D012333:RNA, Messenger / Q000235:genetics; D015427:Reperfusion Injury / Q000188:drug therapy*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014409:Tumor Necrosis Factor-alpha / Q000097:blood / Q000235:genetics
D001600:Berberine Alkaloids; D004365:Drugs, Chinese Herbal; D012333:RNA, Messenger; D014409:Tumor Necrosis Factor-alpha; C525740:yishen; D018799:Intercellular Adhesion Molecule-1; C011188:cavidine